Trials / Completed
CompletedNCT04349267
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BMS-986315 | Specified dose on specified days |
| BIOLOGICAL | nivolumab | Specified dose on specified days |
| BIOLOGICAL | cetuximab | Specified dose on specified days |
Timeline
- Start date
- 2020-07-14
- Primary completion
- 2024-08-22
- Completion
- 2024-08-22
- First posted
- 2020-04-16
- Last updated
- 2025-12-17
- Results posted
- 2025-12-17
Locations
8 sites across 3 countries: United States, Canada, Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04349267. Inclusion in this directory is not an endorsement.